Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA accepts Arpida’s iclaprim NDA
FDA has assigned a standard 10 month review to the iclaprim new drug application (NDA) and has established the Prescription Drug User Fee Act (PDUFA) action date for
FDA has assigned a standard 10 month review to the iclaprim new drug application (NDA) and has established the Prescription Drug User Fee Act (PDUFA) action date for
With the aim to transition the industry from speech recognition to speech understanding, the agreement will incorporate M Modal’s advanced speech technology, AnyModal Conversational Documentation Services (CDS), as
Mr O’Rourke has been serving as senior vice president and general manager, Eastern Division since March 28, 2006. He joined InSight in January 2005, initially as area vice
The data showed that 29% (n=19) of the first 65 evaluable patients enrolled in the trial experienced either a complete or partial response, as assessed by central independent
Salvacyl, a gonadotropin releasing hormone agonist analogue, is said to be effective in the treatment of severe sexual deviations in adult men by inducing and maintaining a reversible
The Phase I protocol calls for a multi-center, open-label, single-arm, dose-escalation trial in the US. Investigators will assess the safety and tolerability of an intravitreal injection of iSONEP
The goal of this Phase II study will be to optimize dosing in order to fully exploit the therapeutic potential of PRX302, while maintaining its excellent safety profile.
The acute coronary syndrome (ACS study), which enrolled 191 patients, is designed to establish dose and safety data in patients with ACS who have experienced a recent heart
The SignatureChip Oligo Solution (SignatureChipOS) is designed for the detection of chromosome abnormalities in individuals with mental retardation/developmental delay, autism and congenital anomalies. The 105,000-feature, 60-mer microarray covers
This is part of a four-year cooperative research and development agreement (CRADA) encompassing multiple Phase I and Phase II clinical studies with correlating translational research of AFP-464 in